Codis
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Codis - overview
Established
1990
Location
Chesterfield, MO, US
Primary Industry
Pharmaceuticals
About
Based in the US, Codis is a Contract Development and Manufacturing Organization (CDMO) focused on providing advanced solutions for pharmaceutical and consumer health industries, particularly in spray drying and particle engineering. Codis, founded in 1990 and headquartered in Chesterfield, US, specializes in contract development and manufacturing. The company has successfully executed a notable deal in October 2025. The founder's history is not publicly documented, nor is there information on previous companies founded by them.
Codis operates as a global CDMO that excels in commercial-scale spray drying, amorphous solid dispersions, and advanced particle engineering services. Key offerings include large-scale production of complex active pharmaceutical ingredients (APIs), co-processed excipients, and spray-dried solid amorphous dispersions. The company also provides microencapsulation, continuous granulation, and finished dose manufacturing, serving clients in North America and Europe while focusing on enhancing bioavailability and improving tableting efficiency. Codis generates its revenue predominantly through B2B contracts with pharmaceutical companies requiring specialized manufacturing and formulation services.
Revenue is driven by long-term partnerships focusing on large-scale production of proprietary formulations, particularly in high-performance materials. The pricing varies based on the complexity and volume of products ordered, with flagship offerings in particle engineering and spray drying significantly contributing to its revenue stream. In October 2025, 1315 Capital, along with BroadOak Capital Partners and Research Corporation Technologies, invested in Codis, enabling the company to accelerate growth and expand its manufacturing capabilities. These funds will support the design and launch of new products while targeting expansion into additional geographical markets.
Specific plans for new market entries are not detailed, but the strategic investment will play a crucial role in enhancing Codis's operational reach.
Current Investors
Research Corporation Technologies, BroadOak Capital Partners, 1315 Capital
Primary Industry
Pharmaceuticals
Sub Industries
Healthcare, Specialty Pharmaceuticals, Paints & Coatings
Website
www.codis.com
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Codis - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | Codis | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.